Atorvastatin, a hypolipidemic medication, is commonly used as oral anti-atherosclerotic and cardiovascular protectant, with multiple marketed tablet brands available. This study aimed to assess critical quality attributes, including in-vitro dissolution characteristics, for five atorvastatin calcium tablet brands (labeled A-E) collected from the Saudi Arabia market. All brands were tested for conformity with the United States Pharmacopoeia (USP) specifications, including evaluation of weight variation, hardness, friability, disintegration time, and dissolution rate. Dissolution profiles were compared with the innovator (brand A) using model-dependent and independent approaches. The samples were compliant with USP specifications for weight variation, disintegration, and dissolution tests; however, brands C and D differed from brand A with respect to disintegration time. All tested tablets showed high hardness and low friability except C, which exhibited a relatively higher friability of 1.38%. All samples had a rapid dissolution profile, with ˃ 89% release rate within 15 min. No significant differences were found with respect to dissolution efficiency and mean dissolution time for all the brands. Although dissolution area under the curve (AUC) values were all in a similar range, brand D AUC was significantly higher than that of A. Lastly, the Weibull model of drug-release kinetics was the best fit for all samples.In conclusion, all atorvastatin calcium tablets examined met USP specifications and reasonably passed the local validation. Only minor variations in critical quality attributes were detected for two brands, suggesting the presence of some differences in tablet manufacturing processes.